Analyses of Human Samples Collected in Clinical Trials
- - INCLUSION CRITERIA: Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer at institutions outside of the intramural NCI are eligible for inclusion, provided that they have consented to pharmacological analysis in the original consent form. EXCLUSION CRITERIA: None anticipated at this time.
Various human samples (e.g., serum, plasma, whole blood, erythrocytes, urine, feces, bile, and/or saliva) will be collected from cancer patients enrolled on approved clinical trials, in accordance with the local protocol. These trials are being conducted at outside institutions, in collaboration with the National Cancer Institute (NCI) and the samples will be sent to the NCI for pharmacological analysis, involving determination of parent drug and/or metabolite concentrations and subsequent pharmacokinetics and statistical data analysis. This study aims to further characterize the clinical pharmacokinetic behavior of select cancer therapeutics. Future collaborators will be added via the protocol amendment procedure.
Trial Phase Phase NA
Trial Type Not provided by clinicaltrials.gov
National Cancer Institute
William Douglas Figg
- Primary ID 999903242
- Secondary IDs NCI-2018-02190, 03-C-N242, NCI-2013-02044
- Clinicaltrials.gov ID NCT00339664